These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 31790543)

  • 1. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
    Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
    JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenfluramine HCl (Fintepla
    Sullivan J; Scheffer IE; Lagae L; Nabbout R; Pringsheim M; Talwar D; Polster T; Galer B; Lock M; Agarwal A; Gammaitoni A; Morrison G; Farfel G
    Epilepsia; 2020 Nov; 61(11):2396-2404. PubMed ID: 33078386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
    Sullivan J; Lagae L; Cross JH; Devinsky O; Guerrini R; Knupp KG; Laux L; Nikanorova M; Polster T; Talwar D; Ceulemans B; Nabbout R; Farfel GM; Galer BS; Gammaitoni AR; Lock M; Agarwal A; Scheffer IE;
    Epilepsia; 2023 Oct; 64(10):2653-2666. PubMed ID: 37543865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
    N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study.
    Gjerulfsen CE; Nikanorova M; Olofsson K; Johannessen Landmark C; Rubboli G; Møller RS
    Epilepsia Open; 2024 Oct; 9(5):1891-1900. PubMed ID: 39140199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
    Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
    Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment.
    Bishop KI; Isquith PK; Gioia GA; Knupp KG; Scheffer IE; Nabbout R; Specchio N; Sullivan J; Auvin S; Helen Cross J; Guerrini R; Farfel G; Galer BS; Gammaitoni AR
    Epilepsy Behav; 2023 Jan; 138():108994. PubMed ID: 36463826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A
    JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
    Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
    Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stiripentol add-on therapy for drug-resistant focal epilepsy.
    Brigo F; Igwe SC; Bragazzi NL
    Cochrane Database Syst Rev; 2020 May; 5(5):CD009887. PubMed ID: 32468572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.